Physician profile
Eric P Jablon
NPI 1215042569
$11,579.06
in general payments reported to CMS, 2019-2025
29 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $1,060 · 2021: $1,156 · 2022: $5,924 · 2023: $1,179 · 2024: $726 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,282 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.13 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $7,045.91 | 2019-2022 | |
| Genentech USA, INC. | $1,023.42 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $761.77 | 2019-2025 | Eylea Hd, Eylea |
| Carl Zeiss Meditec, INC. | $475.66 | 2019-2020 | |
| Abbvie INC. | $298.04 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $236.28 | 2022-2025 | Syfovre |
| Allergan, INC. | $232.28 | 2019-2021 | |
| Eyepoint US, INC. | $196.69 | 2023 | |
| Bausch & Lomb Americas INC. | $189.24 | 2022-2025 | Xipere, Visudyne, Lotemax Sm |
| Novartis Pharmaceuticals Corporation | $160.74 | 2019-2021 | |
| Biogen, INC. | $139.34 | 2022-2023 | |
| Dutch Ophthalmic, USA | $133.90 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $129.97 | 2019-2021 | |
| Coherus Oncology, INC. | $92.44 | 2022-2023 | |
| Optos, INC. | $88.33 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $80.30 | 2019-2024 | Iluvien, Yutiq |
| Sandoz INC. | $54.79 | 2024 | Cimerli |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
| Alcon Vision LLC | $41.94 | 2023-2025 | Rocklatan, Unity |
| Ocular Therapeutix, INC. | $26.13 | 2025 | Dextenza |
| Mallinckrodt Hospital Products INC. | $23.87 | 2022 | |
| Astellas Pharma US INC | $22.17 | 2023 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $17.39 | 2024 | Iheezo |
| Horizon Therapeutics Plc | $17.27 | 2023 | Tepezza |
| Notal Vision, INC. | $15.77 | 2024 | Foresee Home |
| Genentech, INC. | $12.77 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$27,083.33 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Jablon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.